Approval · Notice of Compliance 29385 · 2022

EXELON: Notice of Compliance 29385

Issued November 3, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 29385
Date: November 3, 2022
Company: Knight Therapeutics Inc.Montreal, Quebec, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative: Change in Product Ownership

Products in this notice

Brand	DIN	Status today
EXELON	02242115	Marketed
EXELON	02242116	Marketed
EXELON	02242117	Marketed
EXELON	02242118	Marketed
EXELON	02245240	Marketed

Medicinal ingredients

RIVASTIGMINE 1.5 MG per CAP
RIVASTIGMINE 3 MG per CAP
RIVASTIGMINE 4.5 MG per CAP
RIVASTIGMINE 6 MG per CAP
RIVASTIGMINE HYDROGEN TARTRATE 2 MG per ML